Annals of Oncology Saturno, G, Lopes, F, Niculescu-Duvaz, I, Niculescu-Duvaz, D, Zambon, A, Davies, L, Johnson, L, Preece, N, Lee, R, Viros Usandizaga, A, Holovanchuk, D, Pedersen, M, Mcleary, R, Lorigan, P, Dhomen, N, Fisher, C, Banerji, U, Dean, E, Krebs, M, Gore, M, Larkin, J, Marais, R & Springer, C 2021, ' The paradox-breaking panRAF plus SRC family kinase inhibitor, CCT3833, is effective in mutant KRAS-driven cancers ', Annals of Oncology, vol. 32, no. 2, pp. 269-278 . https://doi.org/10.1016/j.annonc.2020.10.483